SGLT2 + GLP-1 Combination: The Benefits of Dual Therapy for Cardiometabolic Disease | Research

The takeaway

SGLT2i + GLP-1 RA combination therapy provides complementary cardiometabolic benefits through distinct mechanisms, with growing evidence supporting early dual initiation for high-risk patients.

Better together
SGLT2 inhibitors and GLP-1 drugs work through completely different mechanisms — combining them provides cardiometabolic benefits neither achieves alone

What the researchers found

SGLT2i + GLP-1 RA: complementary cardiometabolic mechanisms; combined CV and renal benefits; growing evidence for early dual initiation in high-risk T2D patients.

Why it matters

Choosing between or combining SGLT2i and GLP-1 is a daily clinical decision. Evidence for dual therapy could change treatment algorithms.

How the study worked

Review of SGLT2i + GLP-1 RA combination therapy evidence for cardiometabolic outcomes.

What this study cannot tell us

Most combination evidence from post-hoc analyses. Dedicated combination RCTs limited.

How to read the evidence

Review of combination evidence from trials and observational data.

When this study was published

Published in 2025.

The bigger picture

Combination metabolic therapy parallels combination cardiovascular therapy (statin + ACEi + beta-blocker) — multiple drugs targeting multiple pathways.

Questions still open

Should SGLT2i + GLP-1 be standard initial therapy for high-risk T2D?
Does combination provide additive or synergistic benefits?
Which patients benefit most from combination vs sequential therapy?

Common questions

Should I take both an SGLT2 inhibitor and a GLP-1 drug?

For high-risk diabetic patients, the evidence increasingly supports using both — they work through completely different mechanisms and provide complementary heart and kidney protection.

Is taking two drugs better than one?

In this case, yes. Each drug protects through a different pathway. Together they provide more comprehensive cardiometabolic protection than either alone.

Read the original research

The Beneficial Effects of Combination Therapy With SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.

Current diabetes reviews

View on PubMed ↗Publisher’s paper ↗

Citation

Kalogeris, Aimilianos; Ikonomidis, Ignatios; Kyriakoulis, Konstantinos G; Pavlidis, George; Thymis, John; Katogiannis, Konstantinos; Kountouri, Aikaterini; Pliouta, Loukia; Pililis, Sotirios; Korakas, Emmanouil; Lambadiari, Vaia. (2026). The Beneficial Effects of Combination Therapy With SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.. Current diabetes reviews. https://doi.org/10.2174/0115733998419380251126073540